Back to top
more

Allogene Therapeutics (ALLO)

(Delayed Data from NSDQ)

$2.61 USD

2.61
2,091,270

+0.02 (0.77%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Allogene Therapeutics (ALLO) Up 7.4% Since Last Earnings Report?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs

by Zacks Equity Research

With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.

Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation

by Zacks Equity Research

The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.

Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies

by Zacks Equity Research

Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month.

Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates

by Zacks Equity Research

Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.

Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA

by Zacks Equity Research

The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.

Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold

by Zacks Equity Research

Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.

Company News for Oct 11, 2021

by Zacks Equity Research

Companies in The News Are: ACCD,CCXI,ALLO,WMT

Are Options Traders Betting on a Big Move in Allogene (ALLO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.

Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies

by Zacks Equity Research

The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.

Gilead (GILD) Files sBLA to FDA for Yescarta Label Expansion

by Zacks Equity Research

Gilead's (GILD) wholly owned subsidiary, Kite, submits an sBLA to the FDA for Yescarta to treat relapsed/refractory large B-cell lymphoma in the second-line setting.

Allogene Therapeutics (ALLO) Up 9.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene's (ALLO) CAR T Therapy Gets Orphan Drug Status

by Zacks Equity Research

Allogene's (ALLO) CAR T therapy, ALLO-715, gets orphan-drug designation in the United States. It is a potential treatment for multiple myeloma and other BCMA-positive malignancies.

Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances

by Zacks Equity Research

Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.

Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag

by Zacks Equity Research

Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.

Gilead's (GILD) Kite Announces Positive Data on Yescarta

by Zacks Equity Research

Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.

Why Is Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances

by Zacks Equity Research

Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.

Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.

ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.

Allogene Therapeutics (ALLO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 47.92% and 56.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag

by Zacks Equity Research

FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.

Allogene Therapeutics (ALLO) Up 3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL

by Zacks Equity Research

Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.